Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel

Rhea-AI Summary

Athenex, Inc. (Nasdaq: ATNX) has promoted Teresa Bair to Executive Officer and General Counsel, effective June 23, 2020. With over 23 years of legal experience, she transitions from Senior Vice President, Legal Affairs, and Administration. Bair will oversee global legal matters and lead U.S. administration and government relations. CEO Dr. Johnson Lau praised her valuable counsel and institutional knowledge. Athenex, established in 2003, focuses on developing innovative cancer treatments and has a diverse clinical pipeline.

Positive

• Promotion of Teresa Bair to Executive Officer indicating enhanced leadership.
• Bair's extensive legal background may strengthen corporate governance.
• Continued focus on innovative cancer treatments aligns with market demand.

Negative

• Potential concerns regarding continuity in leadership transition.

BUFFALO, N.Y., June 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the promotion of Teresa Bair, Esq. to Executive Officer as General Counsel and Senior Vice President, Administration.  She will report to Athenex’s Chief Executive Officer.

Ms. Bair, who has more than 23 years of private and in-house legal experience, advances from the position of Senior Vice President, Legal Affairs and Administration.  Since joining Athenex in 2015, she has held various roles with increasing responsibility.  As General Counsel, she will continue overseeing all legal matters of the Company worldwide and serving as Corporate Secretary to the Board of Directors.  As Senior Vice President, Administration, Ms. Bair will lead administration and government relations for U.S. operations and work closely with the Company’s senior management team across the globe.

“Teresa’s valuable legal counsel and unmatched corporate knowledge and experience have made her an institutional asset to Athenex,” stated Dr. Johnson Lau, Athenex’s Chief Executive Officer and Chairman of the Board of Directors.  “She is involved in every aspect of the business and remains fully dedicated to the achievement of our corporate objectives.  Teresa will also continue to play a critical role in advising the Board and leadership team on legal and corporate governance matters. We are delighted to expand her role to that of an Executive Officer and we are confident she will continue to be a strong and prominent leader within Athenex.”

Ms. Bair added, “All of us at Athenex are driven by the prospect of creating new paradigms in the treatment of cancer.  I am excited to take on a new role as Executive Officer and General Counsel as we execute on our mission of bringing innovative cancer treatments to the market and improving health outcomes globally.”

Prior to joining Athenex, Ms. Bair was a partner at Harris Beach PLLC, a nationally recognized law firm, where she successfully represented and advised business clients, including Fortune 500 companies, on complex and diverse matters.  She serves on the Boards of Directors of BirchBioMed Inc., the University at Buffalo Law Alumni Association, and the Western New York Women’s Foundation, as well as the Advisory Boards of Varia Ventures and the Buffalo Institute for Genomics & Data Analytics.  She received her law degree (JD) from University at Buffalo School of Law, and a Bachelor of Science in Business Administration from Bowling Green State University.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.  Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit www.athenex.com.

CONTACTS
Athenex, Inc.:
Randoll Sze
Chief Financial Officer
Email: RandollSze@athenex.com

Jacqueline Li
Corporate Development and Investor Relations
Email: JacquelineLi@athenex.com 

FAQ

What position has Teresa Bair been promoted to at Athenex?

Teresa Bair has been promoted to Executive Officer and General Counsel.

What experience does Teresa Bair bring to her new role at Athenex?

Teresa Bair has over 23 years of legal experience, including various roles at Athenex since 2015.

What are Teresa Bair's responsibilities as General Counsel?

She will oversee all legal matters and serve as Corporate Secretary to the Board of Directors.

What is Athenex's focus in the biopharmaceutical industry?

Athenex is dedicated to the discovery, development, and commercialization of novel therapies for cancer treatment.

When was Teresa Bair's promotion announced?

Her promotion was announced on June 23, 2020.